biopharma-reporter4h
AbbVie’s schizophrenia candidate fails in two phase 2 trials
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...
biopharma-reporter10h
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.
biopharma-reporter5d
Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
biopharma-reporter5d
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...
biopharma-reporter7d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
biopharma-reporter7d
Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC
BigHat will have access to the clinical-stage ADC platform technology designed by Lonza’s Synaffix. The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they ...